US warns of rising counterfeit drug threat from India and China

Latest report highlights increasing concerns over counterfeit pharmaceuticals, IP barriers, and market access challenges | Key countries to watch include India, China, the UAE, and Singapore | Report also outlines challenges in Mexico, Russia, Brazil, and Indonesia.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

22 April 2025 Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.

Big Pharma

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

17 April 2025 Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

US warns of rising counterfeit drug threat from India and China

More on this story

Editor's picks

Editor's picks

More features